Research focus

Kardiovize Brno 2030 is the only population-based cardiovascular health prevention project in Central and Eastern Europe that aims to identify the cardiovascular risk factors of Brno-city population, and to minimize these, by 2030, through tailored preventative programs. The aim of the project is to achieve that the city of Brno has within 20 years the lowest morbidity and mortality from cardiovascular disease in the Czech Republic in persons of working age. We want to make this happen through gradually increasing awareness of risk factors for cardiovascular disease, as well as through shifts in mindset and behavior of the Brno population, thus achieving changes in both levels of risk factors and the occurrence of cardiovascular diseases themselves.

Research objectives

  • Assess changes in prevalence of disease risk factors and disease incidence in the Kardiovize cohort aged 30-79, by a multidisciplinary approach.
  • Design, pilot and evaluate the comprehensive population-based model interventions to improve the cardiovascular and other risk profiles in Kardiovize cohort.
  • Assessment of costs of cardiovascular and other disease risk factors and risk factor interventions.

Main partners

  • Mayo Clinic, Rochester, MN, USA
  • University of Geneva, Geneva, Switzerland
  • Lund University, Lund, Sweden

Technological equipment

  • BIOIMPEDANCE InBody 370 – measuring body composition (using bioimpedance analysis).
  • Air Displacement Plethysmograph Bod Pod - measuring body composition (using the method of AHP).
  • Ultrasound GE Vivid E9 (echocardiography).
  • Ultrasound Essaote (Intima-media thickness).
  • Smokerlyzer Bedfont - measuring carbon monoxide in breath.
  • BVI Scanner – measuring body volume.
  • CAVI Fukuda Denshi – measuring vascular stiffness.

Offered services and expertise

  • Recommended methodology of community intervention programs.
  • Population-focused prevention programs, promotion of health education.
  • Enterprise-focused prevention programs.
  • Monitoring changes in awareness of the risk factors for cardiovascular disease.
  • Laboratory and diagnostic methods.

Top publications

  • GEDA, Y., ROBERTS, R., MIELKE, M., KNOPMAN, D., CHRISTIANSON, T., PANKRATZ, V., BOEVE, B., SOCHOR, O., TANGALOS, E., PETERSEN, R., ROCCA, W. Baseline Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Population-Based Study. American Journal of Psychiatry. 2014, 171(5), 572-581.
  • BLUSTIN, J., MCBANE, R., MAZUR, M., AMMASH, N., SOCHOR, O., GRILL, D., WYSOKINSKI, W. The Association Between Thromboembolic Complications and Blood Group in Patients With Atrial Fibrillation. Mayo Clinic Proceedings. 2015, 90(2), 216-223.
  • PINK, A., STOKIN, GB., BARTLEY, M., ROBERTS, R., SOCHOR, O., MACHULDA, M., KRELL-ROESCH, J., KNOPMAN, S., ACOSTA, J., CHRISTIANSON, T., PANKRATZ, V., MIELKE, M., PETERSEN, R., GEDA, Y. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: A population-based study. Neurology. 2015, 84(9), 935-943.
  • SAHAKYAN, K., SOMERS, V., RODRIGUEZ-ESCUDERO, J., HODGE, D., CARTER, R., SOCHOR, O., COUTINHO, T., JENSEN, M., ROGER, V., SINGH, P., LOPEZ-JIMENEZ, F. Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Annals of Internal Medicine. 2015, 163(11), 827.
  • WOHLFAHRT, P., REDFIELD, M., MELENOVSKY, V., LOPEZ-JIMENEZ, F., RODEHEFFER, R., BORLAUG, B. Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans. European Journal of Heart Failure. 2015, 17(1), 27-34.

Other selected results

Kardiovize 2030 patients database - Kardiovize 2030: In the project’s first phase, was assessed the prevalence of major risk factors of cardiovascular diseases (CVD) in the target population of Brno city (400 000 inhabitants), Czech Republic, performing a randomly selected sample of 2160 volunteers aged 25-64 and following the methodology of the post-MONICA study, enrolled since January 2013 till December 2014. This survey is unique in Europe combining a detailed assessment of the traditional and some novel CVD risk factors with the evaluation of health care costs and including assessment of depression, stress, cognitive tests and resting energy expenditure. Deep frozen samples of plasma, serum or isolated DNA´s in every participant open the study to other disciplines beyond cardiology in the near future.

Team members

  • Jose Pantaleon Hernandez-Rodriguez, Ph.D. MBA MPH
  • Mgr. Jana Jarešová
  • Mgr. Bc. Eva Matuchová
  • Hana Bauerová
  • Mgr. Tereza Dračková
  • Juan Pablo Gonzalez Rivas
  • MUDr. Ota Hlinomaz, CSc.
  • Ing. Jana Hrušková
  • Ing. Juraj Jakubík
  • MUDr. Šárka Kunzová, Ph.D.
  • Andrea Maugeri, MSc
  • Narine Movsisyan, MD
  • Mgr. Iuliia Pavlovska
  • Hana Pernicová Krištofová
  • Mgr. Pavlína Prosecká
  • MUDr. Robert Prosecký, MPH
  • Irma Magaly Rivas Serna, Ph.D.
  • MUDr. Mária Skladaná
  • Ing. Martin Vašek
  • Alena Zajíčková

Principal Investigator

Gorazd Stokin, Ph.D. MD
Gorazd Stokin, Ph.D. MD
Principal Investigator
Phone: +420 54 318 1160